Intrinsic Value of S&P & Nasdaq Contact Us

West Pharmaceutical Services, Inc. WST NYSE

NYSE • Healthcare • Medical - Instruments & Supplies • US • USD

SharesGrow Score
66/100
4/7 Pass
SharesGrow Intrinsic Value
$166.35
-37.9%
Analyst Price Target
$303.33
+13.2%
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

West Pharmaceutical Services, Inc. (WST) trades at a trailing P/E of 38.3, forward P/E of 33.4. Trailing earnings yield is 2.61%, forward earnings yield 2.99%. PEG 23.92. Graham Number is $82.15.

Criteria proven by this page:

  • VALUE (29/100, Fail) — PEG > 2.0 means the stock is expensive even after accounting for growth (PEG 23.92).
  • Forward P/E 33.4 (down from trailing 38.3) — analysts expect earnings to grow, which would improve the valuation.
  • PEG Ratio 23.92 — above 2.0 suggests expensive relative to earnings growth.
  • Trailing Earnings Yield 2.61% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 2.99% as earnings recover.
  • Analyst consensus target $303.33 (+13.2% upside) — modest upside expected.

Overall SharesGrow Score: 66/100 with 4/7 criteria passed.

SharesGrow 7-Criteria Score
66/100
SG Score
View full scorecard →
VALUE
29/100
Price-to-Earnings & upside
Proven by this page
FUTURE
73/100
Analyst consensus
→ Forecast
PAST
100/100
→ Income
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
~
MOAT
57/100
→ Income
GROWTH
30/100
→ Income
INCOME
70/100
→ Income

Valuation Snapshot — WST

Valuation Multiples
P/E (TTM)38.3
Forward P/E33.4
PEG Ratio23.92
Forward PEG1.87
P/B Ratio5.95
P/S Ratio6.12
EV/EBITDA23.7
Per Share Data
EPS (TTM)$6.83
Forward EPS (Est.)$8.02
Book Value / Share$43.93
Revenue / Share$42.51
FCF / Share$6.49
Yields & Fair Value
Earnings Yield2.61%
Forward Earnings Yield2.99%
Dividend Yield0.33%
Graham Number$82.15
SharesGrow IV$166.35 (-37.9%)
Analyst Target$303.33 (+13.2%)

Historical Valuation

Year P/E (TTM) PEG Ratio P/B Ratio P/S Ratio Dividend Yield
2016 43.3 0.91 5.56 4.12 0.58%
2017 48.4 11.85 5.70 4.56 0.54%
2018 35.0 0.94 5.19 4.22 0.58%
2019 46.0 2.74 7.07 6.03 0.41%
2020 60.5 1.40 11.29 9.75 0.23%
2021 52.7 0.58 14.94 12.33 0.15%
2022 29.9 -2.61 6.52 6.07 0.31%
2023 44.1 31.58 9.08 8.87 0.22%
2024 48.5 -3.13 8.91 8.27 0.25%
2025 40.3 34.00 6.26 6.47 0.31%

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2016 $1.91 $1.51B $143.6M 9.5%
2017 $1.99 $1.6B $150.7M 9.4%
2018 $2.74 $1.72B $206.9M 12%
2019 $3.21 $1.84B $241.7M 13.1%
2020 $4.57 $2.15B $346.2M 16.1%
2021 $8.67 $2.83B $661.8M 23.4%
2022 $7.73 $2.89B $585.9M 20.3%
2023 $7.88 $2.95B $593.4M 20.1%
2024 $6.69 $2.89B $492.7M 17%
2025 $6.80 $3.07B $493.7M 16.1%

Analyst Estimates

Year EPS (Avg) EPS Range Revenue (Avg) Revenue Range Analysts
2026 $8.03 $7.49 – $8.19 $3.25B $3.23B – $3.27B 9
2027 $8.88 $8.51 – $9.12 $3.45B $3.43B – $3.48B 9
2028 $10.18 $9.61 – $10.75 $3.7B $3.69B – $3.7B 2
2029 $11.11 $10.95 – $11.26 $3.93B $3.89B – $3.97B 1
2030 $11.36 $11.19 – $11.51 $4.03B $3.98B – $4.07B 1
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message